New targets for rapid antidepressant action

Progress in Neurobiology

Volumn 152, Issue , 2017, Pages 21-37

  Machado Vieira, Rodrigo ^a   Henter, Ioline D ^a   Zarate, Carlos A ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Antidepressant; Bipolar disorder; Depression; Glutamate; Rapid; Treatment

Indexed keywords

AMINO ACID RECEPTOR AFFECTING AGENT; AMPA RECEPTOR; ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; GLUTAMIC ACID; HETERODIMER; IONOTROPIC RECEPTOR; KETAMINE; MAMMALIAN TARGET OF RAPAMYCIN; METABOTROPIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTRANSMITTER; OPIATE RECEPTOR; AMINO ACID RECEPTOR BLOCKING AGENT;

ANTIDEPRESSANT ACTIVITY; BIOLOGICAL MODEL; BRAIN DEPTH STIMULATION; CHOLINERGIC SYSTEM; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG TARGETING; EPIGENETICS; HUMAN; HYPERACTIVITY; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INTRACELLULAR SIGNALING; MOOD DISORDER; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUBLIC HEALTH; RECEPTOR AFFINITY; REVIEW; SLEEP DEPRIVATION; SYNAPTOGENESIS; ANIMAL; BRAIN; CHEMISTRY; DEPRESSION; DRUG DEVELOPMENT; DRUG EFFECTS; EVIDENCE BASED MEDICINE; METABOLISM; TREATMENT OUTCOME; TRENDS;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; DEPRESSION; DRUG DISCOVERY; EVIDENCE-BASED MEDICINE; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; TREATMENT OUTCOME;

EID: 85018492316     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2015.12.001     Document Type: Review

References (227)

1. Abdallah, C.G., Averill, L.A., Krystal, J.H., Ketamine as a promising prototype for a new generation of rapid-acting antidepressants. Ann. N.Y. Acad. Sci. 1344 (2015), 66–77.
2. Ahn, Y.M., Chang, J., Joo, Y.H., Kim, S.C., Lee, K.Y., Chronotype distribution in bipolar I disorder and schizophrenia in a Korean sample. Bipolar Disord. 10 (2008), 271–275.
3. Alaerts, M., Venken, T., Lenaerts, A.S., De Zutter, S., Norrback, K.F., Adolfsson, R., Del-Favero, J., Lack of association of an insertion/deletion polymorphism in the G protein-coupled receptor 50 with bipolar disorder in a Northern Swedish population. Psychiatr. Genet. 16 (2006), 235–236.
4. Armstrong, S.M., McNulty, O.M., Guardiola-Lemaitre, B., Redman, J.R., Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS). Pharmacol. Biochem. Behav. 46 (1993), 45–49.
5. A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study https://clinicaltrials.gov/ct2/show/NCT02158533.
6. Autry, A.E., Adachi, M., Nosyreva, E., Na, E.S., Los, M.F., Cheng, P.F., Kavalali, E.T., Monteggia, L.M., NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475 (2011), 91–95.
7. Ball, W.A., Snavely, D., Hargreaves, R.J., Szegedi, A., Lines, C., Reines, S.A., Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder. Hum. Psychopharmacol. 29 (2014), 568–577.
8. Banasr, M., Soumier, A., Hery, M., Mocaer, E., Daszuta, A., Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis. Biol. Psychiatry 59 (2006), 1087–1096.
9. Bersani, G., Garavani, A., Melatonin add-on in manic patients with treatment resistant insomnia. Biol. Psychiatry 24 (2000), 185–191.
10. Bertaina-Anglade, V., la Rochelle, C.D., Boyer, P.A., Mocaer, E., Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model. Behav. Pharmacol. 17 (2006), 703–713.
11. Beurel, E., Song, L., Jope, R., Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice. Mol. Psychiatry 16 (2011), 1068–1070.
12. Bewernick, B.H., Hurlemann, R., Matusch, A., Kayser, S., Grubert, C., Hadrysiewicz, B., Axmacher, N., Lemke, M., Cooper-Mahkorn, D., Cohen, M.X., Brockmann, H., Lenartz, D., Sturm, V., Schlaepfer, T.E., Nucleus accumbens deep brain stimulation decreases ratings of depression and anxiety in treatment-resistant depression. Biol. Psychiatry 67 (2010), 110–116.
13. Binneman, B., Feltner, D., Kolluri, S., Shi, Y., Qiu, R., Stiger, T., A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. Am. J. Psychiatry 165 (2008), 617–620.
14. Bleakman, D., Alt, A., Witkin, J.M., AMPA receptors in the therapeutic management of depression. CNS Neurol. Disord. Drug Targets 6 (2007), 117–126.
15. Bourin, M., Prica, C., Melatonin receptor agonist agomelatine: a new drug for treating unipolar depression. Curr. Pharm. Des. 15 (2009), 1675–1682.
16. Boyer, P.A., Skolnick, P., Fossom, L.H., Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. A quantitative in situ hybridization study. J. Mol. Neurosci. 10 (1998), 219–233.
17. Bredt, D.S., Furey, M.L., Chen, G., Lovenberg, T., Drevets, W.C., Manji, H.K., Translating depression biomarkers for improved targeted therapies. Neurosci. Biobehav. Rev. 59 (2015), 1–15, 10.1016/j.neubiorev.2015.09.013 Epub 2015 Oct 1.
18. Bunney, B.G., Bunney, W.E., Mechanisms of rapid antidepressant effects of sleep deprivation therapy: clock genes and circadian rhythms. Biol. Psychiatry 15 (2013), 1164–1171.
19. Burch, R.M., A phase 2, randomized, double blind, single intravenous dose study of GLYX-13, an NMDA receptor glycine site functional partial agonist, in subjects with Major Depressive Disorder with inadequate response to antidepressant medication. Presented at the Proceedings of the ACNP 51st Annual Meeting, Hollywood, FL, 2012.
20. Calabrese, J.R., Guelfi, J.D., Perdrizet-Chevalier, C., Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. Bipolar Disord. 9 (2007), 628–635.
21. Cao, R., Cho, H.Y., Lee, B., Obrietan, K., Mammalian target of rapamycin signaling modulates photic entrainment of the suprachiasmatic circadian clock. J. Neurosci. 30 (2010), 6302–6314.
22. Cardinali, D.P., Cano, P., Jimenez-Ortega, V., Esquifino, A.I., Melatonin and the metabolic syndrome: physiopathologic and therapeutical implications. Neuroendocrinology 93 (2011), 133–142.
23. Carlson, P.J., Diazgranados, N., Nugent, A.C., Ibrahim, L., Luckenbaugh, D., Brutsche, N., Herscovitch, P., Manji, H.K., Zarate, C.A.J., Drevets, W.C., Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study. Biol. Psychiatry 73 (2013), 1213–1221.
24. Castren, E., Rantamaki, T., The role of BDNF and its receptors in depression and antidepressant drug action: reactivation of developmental plasticity. Dev. Neurobiol. 70 (2010), 289–297.
25. Chaki, S., Ago, Y., Palucha-Paniewiera, A., Matrisciano, F., Pilc, A., mGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants. Neuropharmacology 66 (2013), 40–52.
26. Chilukuri, H., Reddy, N.P., Pathapati, R.M., Manu, A.N., Jollu, S., Shaik, A.B., Acute antidepressant effects of intramuscular versus intravenous ketamine. Indian J. Psychol. Med. 36 (2014), 71–76.
27. Chowdhury, G.M., Behar, K.L., Cho, W., Thomas, M.A., Rothman, D.L., Sanacora, G., (1)H-[(1)(3)C]-nuclear magnetic resonance spectroscopy measures of ketamine's effect on amino acid neurotransmitter metabolism. Biol. Psychiatry 71 (2012), 1022–1025.
28. Chung, J., Kuo, C.J., Crabtree, G.R., Blenis, J., mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Cell 69 (1992), 1227–1236.
29. Covington, H.E.r., Maze, I., LaPlant, Q.C., Vialou, V.F., Ohnishi, Y.N., Berton, O., Fass, D.M., Renthal, W., Rush, A.J., Wu, E.Y., Ghose, S., Krishnan, V., Russo, S.J., Tamminga, C.A., Haggarty, S.J., Nestler, E.J., Antidepressant actions of histone deacetylase inhibitors. J. Neurosci. 29 (2009), 11451–11460.
30. Covington, H.E.r., Vialou, V.F., Nestler, E.J., From synapse to nucleus: novel targets for treating depression. Neuropharmacology 58 (2010), 683–693.
31. Coyle, C.M., Laws, K.R., The use of ketamine as an antidepressant: a systematic review and meta-analysis. Hum. Psychopharmacol. 30 (2015), 152–163.
32. Cuthbert, B.N., Insel, T.R., Toward the future of psychiatric diagnosis: the seven pillars of RDoC. BMC Med., 11, 2013, 126.
33. Dale, E., Bang-Andersen, B., Sanchez, C., Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs. Biochem. Pharmacol. 95 (2015), 81–97.
34. Danbolt, N.C., Glutamate uptake. Prog. Neurobiol. 65 (2001), 1–105.
35. Dawson, N., McDonald, M., Higham, D.J., Morris, B.J., Pratt, J.A., Subanesthetic ketamine treatment promotes abnormal interactions between neural subsystems and alters the properties of functional brain networks. Neuropsychopharmacology 39 (2014), 1786–1798.
36. Day, J.J., Sweatt, J.D., Epigenetic treatments for cognitive impairments. Neuropsychopharmacology 37 (2012), 247–260.
37. DeLorenzo, C., DellaGioia, N., Bloch, M., Sanacora, G., Nabulsi, N., Abdallah, C.G., Yang, J., Wen, R., Mann, J.J., Krystal, J.H., Parsey, R.V., Carson, R.E., Esterlis, I., Invivo ketamine-induced changes in [C]ABP688 binding to metabotropic glutamate receptor subtype 5. Biol. Psychiatry 77 (2015), 266–275.
38. Denk, M.C., Rewarts, C., Holsboer, F., Erhardt-Lehmann, A., Turck, C.W., Monitoring ketamine treatment response in a depressed patient via peripheral mammalian target of rapamycin activation. Am. J. Psychiatry 68 (2011), 751–752.
39. Deschwanden, A., Karolewicz, B., Feyissa, A.M., Treyer, V., Ametamev, S.M., Johayem, A., Burger, C., Auberson, Y.P., Sovago, J., Stockmeier, C.A., Buck, A., Hasler, G., Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study. Am. J. Psychiatry 168 (2011), 727–734.
40. Drevets, W.C., Zarate, C.A.J., Furey, M.L., Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review. Biol. Psychiatry 73 (2013), 1156–1163.
41. Driesen, N.R., McCarthy, G., Bhagwagar, Z., Bloch, M., Calhoun, V., D'Souza, D.C., Gueorguieva, R., He, G., Ramachandran, R., Suckow, R.F., Anticevic, A., Morgan, P.T., Krystal, J.H., Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans. Mol. Psychiatry 18 (2013), 1199–1204.
42. Duman, C.H., Duman, R.S., Spine synapse remodeling in the pathophysiology and treatment of depression. Neurosci. Lett. 601 (2015), 20–29 Aug 5.
43. Duman, R.S., Neuronal damage and protection in the pathophysiology and treatment of psychiatric illness: stress and depression. Dialogues Clin. Neurosci. 11 (2009), 239–255.
44. Duman, R.S., Aghajanian, G.K., Synaptic dysfunction in depression: potential therapeutic targets. Science 338 (2012), 68–72.
45. Duman, R.S., Li, N., Liu, R.J., Duric, V., Aghajanian, G.K., Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 62 (2012), 35–41.
46. Duncan, W.C., Sarasso, S., Ferrarelli, F., Selter, J., Riedner, B.A., Hejazi, N.S., Yuan, P., Brutsche, N., Manji, H.K., Tononi, G., Zarate, C.A.J., Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. Int. J. Neuropsychopharmacol. 16 (2013), 301–311.
47. Dutta, A., McKie, S., Deakin, J.F., Ketamine and other potential glutamate antidepressants. Psychiatry Res. 225 (2015), 1–13.
48. Dwyer, J.M., Duman, R.S., Activation of mammalian target of rapamycin and synaptogenesis: role in the actions of rapid-acting antidepressants. Biol. Psychiatry 73 (2013), 1189–1198.
49. Dwyer, J.M., Lepack, A.E., Duman, R.S., mTOR activation is required for the antidepressant effects of mGluR(2)/(3) blockade. Int. J. Neuropsychopharmacol. 15 (2012), 429–434.
50. Ehrich, E., Turncliff, R., Du, Y., Leigh-Pemberton, R., Fernandez, E., Jones, R., Fava, M., Evaluation of opioid modulation in major depressive disorder. Neuropsychopharmacology 40 (2015), 1448–1455.
51. Emnett, C.M., Eisenman, L.N., Taylor, A.M., Izumi, Y., Zorumski, C.F., Mennerick, S., Indistinguishable synaptic pharmacodynamics of the N-methyl-D-aspartate receptor channel blockers memantine and ketamine. Mol. Pharmacol. 84 (2013), 935–947.
52. Espino, J., Pariente, J.A., Rodriguez, A.B., Role of melatonin on diabetes-related metabolic disorders. World J. Diabetes 2 (2011), 82–91.
53. Furey, M.L., Drevets, W.C., Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch. Gen. Psychiatry 63 (2006), 1121–1129.
54. Garcia, L.S., Comim, C.M., Valvassori, S.S., Reus, G.Z., Barbosa, L.M., Andreazza, A.C., Stertz, L., Fries, G.R., Gavioli, E.C., Kapczinski, F., Quevedo, J., Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog. Neuropsychopharmacol. Biol. Psychiatry 32 (2008), 140–144.
55. Geoffrey, P.A., Etain, B., Franchi, J.A., Bellivier, F., Ritter, P., Melatonin and melatonin agonists as adjunctive treatments in bipolar disorders. Curr. Pharm. Des. 21 (2015), 3352–3358.
56. Gideons, E., Kavalali, E.T., Monteggia, L.M., Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses. Proc. Natl. Acad. Sci. U.S.A. 111 (2014), 8649–8654.
57. Gigliucci, V., O'Dowd, G., Casey, S., Egan, D., Gibney, S., Harkin, A., Ketamine elicits sustained antidepressant-like activity via a serotonin-dependent mechanism. Psychopharmacology (Berl.) 228 (2013), 157–166.
58. Gonzalez-Maeso, J., Ang, R.L., Yuen, T., Chan, P., Weisstaub, N.V., Lopez-Gimenez, J.F., Zhou, M., Okawa, Y., Callado, L.F., Milligan, G., Gingrich, J.A., Filizola, M., Meana, J.J., Sealfon, S.C., Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 452 (2008), 93–97.
59. Goodwin, G.M., Emsley, R., Rembry, S., Rouillon, F., Agomelatine Study Group. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 70 (2009), 1128–1137.
60. Gruber, J., Harvey, A.G., Wang, P.W., Brooks, J.O. r, Thase, M.E., Sachs, G.S., Ketter, T.A., Sleep functioning in relation to mood, function, and quality of life at entry to the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). J. Affect Disord. 114 (2009), 41–49.
61. Guertin, D.A., Sabatini, D.M., Defining the role of mTOR in cancer. Cancer Cell 12 (2007), 9–22.
62. Haile, C.N., Murrough, J.W., Iosifescu, D.V., Chang, L.C., Al Jurdi, R.K., Foulkes, A., Iqbal, S., Mahoney, J.J.r., De La Garza, R.n., Charney, D.S., Newton, T.F., Mathew, S.J., Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. Int. J. Neuropsychopharmacol. 17 (2014), 331–336.
63. Hallam, K.T., Olver, J.S., Chambers, V., Begg, D.P., McGrath, C., Norman, T.R., The heritability of melatonin secretion and sensitivity to bright nocturnal light in twins. Psychoneuroendocrinology 31 (2006), 867–875.
64. Hallam, K.T., Olver, J.S., Horgan, J.E., McGrath, C., Norman, T.R., Low doses of lithium carbonate reduce melatonin light sensitivity in healthy volunteers. Int. J. Neuropsychopharmacol. 8 (2005), 255–259.
65. Hallam, K.T., Olver, J.S., Norman, T.R., Effect of sodium valproate on nocturnal melatonin sensitivity to light in healthy volunteers. Neuropsychopharmacology 30 (2005), 1400–1404.
66. Hallam, K.T., Olver, J.S., Norman, T.R., Melatonin sensitivity to light in monozygotic twins discordant for bipolar I disorder. Aust. N.Z. J. Psychiatry, 39, 2005, 947.
67. Harvey, A.G., Sleep and circadian rhythms in bipolar disorder: seeking synchrony, harmony, and regulation. Am. J. Psychiatry 165 (2008), 820–829.
68. Hashimoto, K., Sawa, A., Iyo, M., Increased levels of glutamate in brains from patients with mood disorders. Biol. Psychiatry 62 (2007), 1310–1316.
69. Heitman, J., Movva, N., Hall, M.N., Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253 (1991), 905–909.
70. Hirota, K., Lambert, D.J., Ketamine: its mechanism(s) of action and unusual clinical uses. Br. J. Anaesth. 77 (1996), 441–444.
71. Hirota, K., Okawa, H., Appadu, B.L., Grandy, D.K., Devi, L.A., Lambert, D.G., Stereoselective interaction of ketamine with recombinant μ, κ and δ opiod receptors expressed in chinese hamster ovary cells. Anesthesiology 90 (1999), 174–182.
72. Hoeffer, C.A., Klann, E., mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci. 33 (2010), 67–75.
73. Hong, L.E., Summerfelt, A., Buchanan, R.W., O'Donnell, P., Thaker, G.K., Weiler, M.A., Lahti, A.C., Gamma and delta neural oscillations and association with clinical symptoms under subanesthetic ketamine. Neuropsychopharmacology 35 (2010), 632–640.
74. Ibrahim, L., Diazgranados, N., Franco-Chaves, J., Brutsche, N., Henter, I.D., Kronstein, P., Moaddel, R., Wainer, I., Luckenbaugh, D.A., Manji, H.K., Zarate, C.A., Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology 37 (2012), 1526–1533.
75. Ibrahim, L., Diazgranados, N., Jolkovsky, L., Brutsche, N., Luckenbaugh, D., Herring, W.J., Potter, W.Z., Zarate, C.A.J., A randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J. Clin. Psychopharmacol. 32 (2012), 551–557.
76. Jaffe, R.J., Novakovic, V., Peselow, E.D., Scopolamine as an antidepressant: a systematic review. Clin. Neuropharmacol. 36 (2013), 24–26.
77. Jernigan, C.S., Goswami, D.B., Austin, M.C., Iyo, A.H., Chandran, A., Stockmeier, C.A., Karolewicz, B., The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 35 (2011), 1774–1779.
78. Johnson, S.C., Rabinovitch, P.S., Kaeberlein, M., mTOR is a key modulator of ageing and age-related disease. Nature 493 (2013), 338–345.
79. Jourdi, H., Hsu, Y.T., Zhou, M., Qin, Q., Bi, X., Baudry, M., Positive AMPA receptor modulation rapidly stimulates BDNF release and increases dendritic mRNA translation. J. Neurosci. 29 (2009), 8688–8697.
80. Karasawa, J., Shimazaki, T., Kawashima, N., Chaki, S., AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist. Brain Res. 1042 (2005), 92–98.
81. Katz, M.M., Tekell, J.L., Bowden, C.L., Brannan, S., Houston, J.P., Berman, N., Frazer, A., Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology 29 (2004), 566–579.
82. Keller, M., Montgomery, S., Ball, W.A., Morrison, M., Snavely, D., Liu, G., Hargreaves, R.J., Hietala, J., Lines, C., Beebe, K., Reines, S.A., Lack of efficacy of the substance P (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol. Psychiatry 59 (2006), 216–223.
83. Kennedy, S.H., Emsley, R., Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur. Neuropsychopharmacol. 16 (2006), 93–100.
84. Kennedy, S.H., Kutcher, S.P., Ralveski, E., Brown, G.M., Nocturnal melatonin and 24-hour 6-sulphatoxymelatonin levels in various phases of bipolar affective disorder. Psychiatry Res. 63 (1996), 219–222.
85. Khajavi, D., Farokhnia, M., Modabbernia, A., Ashrafi, M., Abbasi, S.H., Tabrizi, M., Akhondzadeh, S., Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 73 (2012), 1428–1433.
86. Klimek, V., Papp, M., The effect of MK-801 and imipramine on beta-adrenergic and 5-HT2 receptors in the chronic mild stress model of depression in rats. Pol. J. Pharmacol. 46 (1994), 67–69.
87. Knoll, A.T., Carlezon, W.A. Jr., Dynorphin, stress, and depression. Brain Res. 1314 (2010), 56–73.
88. Kocsis, B., Brown, R.E., McCarley, R.W., Hajos, M., Impact of ketamine on neuronal network dynamics: translational modeling of schizophrenia-relevant deficits. CNS Neurosci. Ther. 19 (2013), 437–447.
89. Koike, H., Iijima, M., Chaki, S., Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res. 224 (2011), 107–111.
90. Koshikawa, N., Maruyama, Y., Kobayashi, M., Campbell, I.C., Rapid development of brain beta-adrenoceptor down-regulation induced by phenelzine: subcellular studies. Eur. J. Pharmacol. 170 (1989), 101–104.
91. Kotermanski, S.E., Wood, J.T., Johnson, J.W., Memantine binding to a superficial site on NMDA receptors contributes to partial trapping. J. Physiol. 587 (2009), 4589–4604.
92. Kozirog, M., Poliwczak, A.R., Duchnowicz, P., Koter-Michalak, M., Sikora, J., Broncel, M., Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome. J. Pineal Res. 50 (2011), 261–266.
93. Kramer, M.S., Cutler, N., Feighner, J., Shrivastava, R., Carman, J., Sramek, J.J., Reines, S.A., Liu, G., Snavely, D., Wyatt-Knowles, E., Hale, J.J., Mills, S.G., MacCoss, M., Swain, C.J., Harrison, T., Hill, R.G., Hefti, F., Scolnick, E.M., Cascieri, M.A., Chicchi, G.G., Sadowski, S., Williams, A.R., Hewson, L., Smith, D., Carlson, E.J., Hargreaves, R.J., Rupniak, N.M., Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281 (1998), 1640–1645.
94. Kramer, M.S., Winokur, A., Kelsey, J., Preskorn, S.H., Rothschild, A.J., Snavely, D., Ghosh, K., Ball, W.A., Reines, S.A., Munjack, D., Apter, J.T., Cunningham, L., Kling, M., Bari, M., Getson, A., Lee, Y., Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 29 (2004), 385–392.
95. Lai, T.W., Zhang, S., Wang, Y.T., Excitotoxicity and stroke: identifying novel targets for neuroprotection. Prog. Neurobiol. 115 (2014), 157–188.
96. Lapidus, K.A., Levitch, C.F., Perez, A.M., Brallier, J.W., Parides, M.K., Soleimani, L., Feder, A., Iosifescu, D.V., Charney, D.S., Murrough, J.W., A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol. Psychiatry 76:12 (2014), 970–976 Dec 15.
97. Laposky, A.D., Bass, J., Kohsaka, A., Turek, F.W., Sleep and circadian rhythms: key components in the regulation of energy metabolism. FEBS Lett. 582 (2008), 142–151.
98. Lauterbach, E.C., Dextromethorphan as a potential rapid-acting antidepressant. Med. Hypotheses 76 (2011), 717–719.
99. Layer, R.T., Popik, P., Olds, T., Skolnick, P., Antidepressant-like actions of the polyamine site NMDA antagonist, eliprodil (SL-82.0715). Pharmacol. Biochem. Behav. 52 (1995), 621–627.
100. Lee, S.Y., Chen, S.L., Chang, Y.H., Chen, S.H., Chu, C.H., Huang, S.Y., Tzeng, N.S., Wang, C.L., Lee, I.H., Yeh, T.L., Yang, Y.K., Lu, R.B., The DRD2/ANKK1 gene is associated with response to add-on dextromethorphan treatment in bipolar disorder. J. Affect Disord. 138 (2012), 295–300.
101. Legutko, B., Li, X., Skolnick, P., Regulation of BDNF expression in primary neuron culture by LY392098, a novel AMPA receptor potentiator. Neuropharmacology 40 (2001), 1019–1027.
102. Leibenluft, E., Feldman-Naim, S., Turner, E.H., Wehr, T.A., Rosenthal, N.E., Effects of exogenous melatonin administration and withdrawal in five patients with rapid-cycling bipolar disorder. J. Clin. Psychiatry 58 (1997), 383–388.
103. Lewy, A.J., Nurnberger, J.I. Jr., Wehr, T.A., Pack, D., Becker, L.E., Powell, R.L., Newsome, D.A., Supersensitivity to light: possible trait marker for manic-depressive illness. Am. J. Psychiatry 142 (1985), 725–727.
104. Lewy, A.J., Wehr, T.A., Goodwin, F.K., Newsome, D.A., Rosenthal, N.E., Manic-depressive patients may be supersensitive to light. Lancet 1 (1981), 383–384.
105. Li, N., Lee, B., Liu, R.J., Banasr, M., Dwyer, J.M., Iwata, M., Li, X.Y., Aghajanian, G.K., Duman, R.S., mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329 (2010), 959–964.
106. Li, N., Liu, R.J., Dwyer, J.M., Banasr, M., Lee, B., Son, H., Li, X.Y., Aghajanian, G., Duman, R.S., Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol. Psychiatry 69 (2011), 754–761.
107. Linden, A.M., Valsanen, J., Lakso, M., Nawa, H., Wong, G., Castren, E., Expression of neurotrophins BDNF and NT-3, and their receptors in rat brain after administration of antipsychotic and psychotropic agents. J. Mol. Neurosci. 14 (2000), 27–37.
108. Liu, H.F., Zhou, W.H., Xie, X.H., Cao, J.L., Gu, J., Yang, G.D., Muscarinic receptors modulate the mRNA expression of NMDA receptors in brainstem and the release of glutamate in periaqueductal grey during morphine withdrawal in rats. Sheng Li Xue Bao 56 (2004), 95–100.
109. Livingstone, M., Atas, E., Meller, A., Sonenberg, N., Mechanisms governing the control of mRNA translation. Phys. Biol., 7, 2010, 021001.
110. Loo, H., Hale, A., D'Haenen, H., Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int. Clin. Psychopharmacol. 17 (2002), 239–247.
111. Lozano, A.M., Mayberg, H.S., Giacobbe, P., Hamani, C., Craddock, R.C., Kennedy, S.H., Effects of subcallosal cingulate deep brain stimulation on negative self-bias in patients with treatment-resistant depression. Biol. Psychiatry 64 (2008), 461–467.
112. Luckenbaugh, D., Niciu, M.J., Ionescu, D.F., Nolan, N.M., Richards, E.M., Brutsche, N., Guevara, S., Zarate, C.A.J., Do the dissociative side effects of ketamine mediate its antidepressant effects. J. Affect Disord. 159 (2014), 56–61.
113. Machado-Vieira, R., Baumann, J., Wheeler-Castillo, C., Latov, D., Henter, I.D., Salvadore, G., Zarate, C.A.J., The timing of antidepressant effects: a comparison of diverse pharmacological and somatic treatments. Pharmaceuticals 3 (2010), 19–41.
114. Machado-Vieira, R., Ibrahim, L., Henter, I.D., Zarate, C.A. Jr., Novel glutamatergic agents for major depressive disorder and bipolar disorder. Pharmacol. Biochem. Behav. 100 (2012), 678–687.
115. Machado-Vieira, R., Ibrahim, L., Zarate, C.A.J., Histone deacetylases and mood disorders: epigenetic programming in gene-environment interactions. CNS Neurosci. Ther. 17 (2011), 699–704.
116. Machado-Vieira, R., Manji, H.K., Zarate, C.A., The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist 15 (2009), 525–539.
117. Machado-Vieira, R., Salvadore, G., Ibrahim, L.A., Diaz-Granados, N., Zarate, C.A. Jr., Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders. Curr. Pharm. Des. 15 (2009), 1595–1611.
118. Machado-Vieira, R., Yuan, P., Brutsche, N., DiazGranados, N., Luckenbaugh, D., Manji, H.K., Zarate, C.A. Jr., c. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J. Clin. Psychiatry 70 (2009), 1662–1666.
119. Machado-Vieira, R., Salvadore, G., Luckenbaugh, D.A., Manji, H.K., Zarate, C.A.J., Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depression. J. Clin. Psychiatry 69 (2008), 946–958.
120. Machado-Vieira, R., Soeiro-de-Souza, M.G., Richards, E.M., Teixeira, A.L., Zarate, C.A.J., Multiple levels of impaired neural plasticity and cellular resilience in bipolar disorder: developing treatments using an integrated translational approach. World J Biol. Psychiatry 15 (2014), 84–95.
121. Machado-Vieira, R., Zanetti, M.V., Teixeira, A.L., Uno, M., Valiengo, L.L., Soeiro-de-Souza, M.G., Oba-Shinjo, S.M., de Sousa, R.T., Zarate, C.A.J., Gattaz, W.F., Marie, S.K., Decreased AKT1/mTOR pathway mRNA expression in short-term bipolar disorder. Eur. Neuropsychopharmacol. 25 (2015), 468–473.
122. Maeng, S., Zarate, C.A. Jr., Du, J., Schloesser, R.J., McCammon, J., Chen, G., Manji, H.K., Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol. Psychiatry 63 (2008), 349–352.
123. Maes, M., Verkerk, R., Vandoolaeghe, E., Lin, A., Scharpe, S., Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity. Acta Psychiatr. Scand. 97 (1998), 302–308.
124. Maj, J., Rogoz, Z., Skuza, G., Antidepressant drugs increase the locomotor hyperactivity induced by MK-801 in rats. J. Neural Transm. Gen. Sect. 85 (1991), 169–179.
125. Malenka, R.C., Bear, M.F., LTP and LTD: an embarrassment of riches. Neuron 44 (2004), 5–21.
126. Malone, D.A.J., Dougherty, D.D., Rezai, A.R., Carpenter, L.L., Friehs, G.M., Eskandar, E.N., Rauch, S.L., Rasmussen, S.A., Machado, A.G., Kubu, C.S., Tyrka, A.R., Price, L.H., Stypulkowski, P.H., Giftakis, J.E., Rise, M.T., Malloy, P.F., Salloway, S.P., Greenberg, B.D., Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression. Biol. Psychiatry 65 (2009), 267–275.
127. Mansour, H.A., Wood, J., Chowdari, K.V., Dayal, M., Thase, M.E., Kupfer, D.J., Monk, T.H., Devlin, B., Nimgainkar, V.L., Circadian phase variation in bipolar I disorder. Chronobiol. Int. 22 (2005), 571–584.
128. McClung, C.A., Circadian genes, rhythms and the biology of mood disorders. Pharmacol. Ther. 114 (2007), 222–232.
129. Mealing, G.A., Lanthorn, T.H., Murray, C.L., Small, D.L., Morley, P., Differences in degree of trapping of low-affinity uncompetitive N-methyl-D-aspartic acid receptor antagonists with similar kinetics of block. J. Pharmacol. Exp. Ther. 288 (1999), 204–210.
130. Meloni, D., Gambarana, C., De Montis, M.G., Dal Pra, P., Taddei, I., Tagliamonte, A., Dizocilpine antagonizes the effect of chronic imipramine on learned helplessness in rats. Pharmacol. Biochem. Behav. 46 (1993), 423–426.
131. Menniti, F.S., Lindsley, C.W., Conn, P.J., Pandit, J., Zagouras, P., Volkmann, R.A., Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks. Curr. Top. Med. Chem. 13 (2013), 26–54.
132. Messias, E., Everett, B., Dextromethorphan and quinidine combination in emotional lability associated with depression: a case report. Prim Care Companion CNS Disord, 14, 2012, I01400 (PCC.12).
133. Millan, M.J., Brocco, M., Gobert, A., Dekeyne, A., Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology (Berl.) 177 (2005), 448–458.
134. Mjellem, N., Lund, A., Hole, K., Reduction of NMDA-induced behaviour after acute and chronic administration of desipramine in mice. Neuropharmacology 32 (1993), 591–595.
135. Moaddel, R., Luckenbaugh, D., Xie, Y., Villasenor, A., Brutsche, N.E., Machado-Vieira, R., Ramamoorthy, A., Lorenzo, M.P., Garcia, A., Bernier, M., Torjman, M.C., Barbas, C., Zarate, C.A.J., Wainer, I.W., D-serine plasma concentration is a potential biomarker of (R,S)-ketamine antidepressant response in subjects with treatment-resistant depression. Psychopharmacology (Berl.) 232 (2015), 399–409.
136. Moghaddam, B., Adams, B., Verma, A., Daly, D., Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 17 (1997), 2921–2927.
137. Monteggia, L.M., Gideons, E., Kavalali, E.T., The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine. Biol. Psychiatry 73 (2013), 1199–1203.
138. Montgomery, S.A., Kasper, S., Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int. Clin. Psychopharmacol. 22 (2007), 283–291.
139. Moryl, E., Danysz, W., Quack, G., Potential antidepressive properties of amantadine, memantine and bifemelane. Pharmacol. Toxicol. 72 (1993), 394–397.
140. Moskal, J.R., Burch, R., Burgdorf, J.S., Kroes, R.A., Stanton, P.K., Disterhoft, J.F., Leander, J.D., GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists. Expert. Opin. Investig. Drugs 23 (2014), 243–254.
141. Musazzi, L., Treccani, G., Mallei, A., Popoli, M., The action of antidepressants on the glutamate system: regulation of glutamate release and glutamate receptors. Biol. Psychiatry 73 (2013), 1180–1188.
142. Nagayama, H., Chronic administration of imipramine and lithium changes the phase-angle relationship between the activity and core body temperature circadian rhythms in rats. Chronobiol. Int. 13 (1996), 251–259.
143. Nagele, P., Duma, A., Kopec, M., Gebara, M.A., Parsoei, A., Walker, M., Janski, A., Panagopoulos, V.N., Cristancho, P., Miller, J.P., Zorumski, C.F., Conway, C.R., Nitrous oxide for treatment-resistant major depression: a proof-of-concept trial. Biol. Psychiatry 78 (2015), 10–18.
144. Nathan, P.J., Burrows, G.D., Norman, T.R., Melatonin sensitivity to dim white light in affective disorders. Neuropsychopharmacology 21 (1999), 408–413.
145. Nations, K.R., Dogterom, P., Bursi, R., Schipper, J., Greenwald, S., Zraket, D., Gertsik, L., Johnstone, J., Lee, A., Pande, Y., Ruigt, G., Ereshefsky, L., Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: an exploratory, randomized, double-blind, placebo-controlled trial. J. Psychopharmacol. 26 (2012), 1525–1539.
146. Navarria, A., Wohleb, E.S., Voleti, B., Ota, K.T., Dutheil, S., Lepack, A.E., Dwyer, J.M., Fuchikami, M., Becker, A., Drago, F., Duman, R.S., Rapid antidepressant actions of scopolamine: role of medial prefrontal cortex and M1-subtype muscarinic acetylcholine receptors. Neurobiol. Dis. 82 (2015), 254–261.
147. Nduhirabandi, F., Du Toit, E.F., Blackhurst, D., Marais, D., Lochner, A., Chronic melatonin consumption prevents obesity-related metabolic abnormalities and protects the heart against myocardial ischemia and reperfusion injury in a prediabetic model of diet-induced obesity. J. Pineal Res. 50 (2011), 171–182.
148. Neubauer, D.N., A review of ramelteon in the treatment of sleep disorders. Neuropsychiatr. Dis. Treat. 4 (2008), 69–79.
149. Nguyen, L., Matsumoto, R.R., Involvement of AMPA receptors in the antidepressant-like effects of dextromethorphan in mice. Behav Brain Res. 295 (2015), 26–34 Dec 15.
150. Niciu, M.J., Henter, I.D., Luckenbaugh, D.A., Zarate, C.A.J., Charney, D.S., Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. Annu. Rev. Pharmacol. Toxicol. 54 (2014), 119–139.
151. Nishimura, M., Sato, K., Okada, T., Yoshiya, I., Schloss, P., Shimada, S., Tohyama, M., Ketamine inhibits monoamine transporters expressed in human embryonic kidney 293 cells. Anesthesiology 88 (1998), 768–774.
152. Norris, E.R., Burke, K., Correll, J.R., Zemanek, K.J., Lerman, J., Primelo, R.A., Kaufmann, M.W., A double-blind, randomized, placebo-controlled trial of adjunctive ramelteon for the treatment of insomnia and mood stability in patients with euthymic bipolar disorder. J. Affect Disord. 144 (2013), 141–147.
153. Nosyreva, E., Szabla, K., Autry, A.E., Ryazanov, A.G., Monteggia, L.M., Kavalali, E.T., Acute suppression of spontaneous neurotransmission drives synaptic potentiation. J. Neurosci. 33 (2013), 6990–7002.
154. Nowak, G., Legutko, B., Skolnick, P., Popik, P., Adaptation of cortical NMDA receptors by chronic treatment with specific serotonin reuptake inhibitors. Eur. J. Pharmacol. 342 (1998), 367–370.
155. Nowak, G., Trullas, R., Layer, R.T., Skolnick, P., Paul, I.A., Adaptive changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid. J. Pharmacol. Exp. Ther. 265 (1993), 1380–1386.
156. Nurnberger, J.I. Jr., Adkins, S., Lahiri, D.K., Mayeda, A., Hu, K., Lewy, A., Miller, A., Bowman, E.S., Miller, M.J., Rau, L., Smiley, C., Davis-Singh, D., Melatonin suppression by light in euthymic bipolar and unipolar patients. Arch. Gen. Psychiatry 57 (2000), 572–579.
157. Nurnberger, J.I. Jr., Berrettini, W., Tamarkin, L., Hamovit, J., Norton, J., Gershon, E., Supersensitivity to melatonin suppression by light in young people at high risk for affective disorder. A preliminary report. Neuropsychopharmacology 1 (1988), 217–223.
158. O'Neill, M.F., Sanger, G.J., A single pretreatment with MK-801 or cocaine enhances their locomotor stimulant effects in rats. Brain Res. 834 (1999), 103–111.
159. O'Neill, M.J., Bleakman, D., Zimmerman, D.M., Nisenbaum, E.S., AMPA receptor potentiators for the treatment of CNS disorders. Curr. Drug Targets CNS Neurol. Disord. 3 (2004), 181–194.
160. O'Neill, M.J., Witkin, J.M., AMPA receptor potentiators: application for depression and Parkinson's disease. Curr. Drug Targets 8 (2007), 603–620.
161. Ohgi, Y., Futamura, T., Hashimoto, K., Glutamate signaling in synaptogenesis and NMDA receptors as potential therapeutic targets for psychiatric disorders. Curr. Mol. Med. 15 (2015), 206–221.
162. Pacchierotti, C., Iapichino, S., Bossini, L., Pieraccini, F., Castrogiovanni, P., Melatonin in psychiatric disorders: a review on the melatonin involvement in psychiatry. Front. Neuroendocrinol. 22 (2001), 18–32.
163. Pandi-Perumal, S.R., Srinivasan, V., Maestroni, G.J., Cardinali, D.P., Poeggeler, B., Hardeland, R., Melatonin: nature's most versatile biological signal?. FEBS J. 273 (2006), 2813–2838.
164. Papp, M., Gruca, P., Boyer, P.A., Mocaer, E., Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology 28 (2003), 694–703.
165. Papp, M., Moryl, E., Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression. Eur. J. Pharmacol. 263 (1994), 1–7.
166. Paul, I.A., Nowak, G., Layer, R.T., Popik, P., Skolnick, P., Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments. J. Pharmacol. Exp. Ther. 269 (1994), 95–102.
167. Paul, I.A., Trullas, R., Skolnick, P., Nowak, G., Down-regulation of cortical beta-adrenoceptors by chronic treatment with functional NMDA antagonists. Psychopharmacology (Berl.) 106 (1992), 285–287.
168. Paul, S.M., Mytelka, D.S., Dunwiddie, C.T., Persinger, C.C., Munos, B.H., Lindborg, S.R., Schacht, A.L., How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9 (2010), 203–214.
169. Petty, F., McChesney, C., Kramer, G., Intracortical glutamate injection produces helpless-like behavior in the rat. Pharmacol. Biochem. Behav. 22 (1985), 531–533.
170. Pilc, A., Wieronska, J.M., Skolnick, P., Glutamate-based antidepressants: preclinical psychopharmacology. Biol. Psychiatry 73 (2013), 1125–1132.
171. Pozzi, L., Dorocic, I.P., Wang, X., Carlen, M., Meletis, K., Mice lacking NMDA receptors in parvalbumin neurons display normal depression-related behavior and response to antidepressant action of NMDAR antagonists. PLoS One, 9, 2014, e83879.
172. Preskorn, S.H., Baker, B., Kolluri, S., Menniti, F.S., Krams, M., Landen, J.W., An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist CP-101,606, in patients with treatment-refractory major depressive disorder. J. Clin. Psychopharmacol. 28 (2008), 631–637.
173. Przegalinski, E., Tatarczynska, E., Deren-Wesolek, A., Chojnacka-Wojcik, E., Antidepressant-like effects of a partial agonist at strychnine-insensitive glycine receptors and a competitive NMDA receptor antagonist. Neuropharmacology 36 (1997), 31–37.
174. Quiroz, J.A., Tamburri, P., Deptula, D., Banken, L., Beyer, U., Fontoura, P., Santarelli, L., The efficacy and safety of basimglurant as adjunctive therapy in major depression; a randomized, double-blind, placebo controlled study. Neuropsychopharmacology 39 (2014), S376–S377.
175. Rantamaki, T., Castren, E., Targeting TrkB neurotrophin receptor to treat depression. Expert Opin Ther Targets 12 (2008), 705–715.
176. Rawls, S.M., McGinty, J.F., Muscarinic receptors regulate extracellular glutamate levels in the rat striatum: An in vivo microdialysis study. J. Pharmacol. Exp. Ther. 286 (1998), 91–98.
177. Redman, J.R., Francis, A.J., Entrainment of rat circadian rhythms by the melatonin agonist S-20098 requires intact suprachiasmatic nuclei but not the pineal. J. Biol. Rhythms 13 (1998), 39–51.
178. Reiter, R.J., Paredes, S.D., Manchester, L.C., Tan, D.X., Reducing oxidative/nitrosative stress: a newly-discovered genre for melatonin. Crit. Rev. Biochem. Mol. Biol. 44 (2009), 175–200.
179. 3H]MK801 binding to the N-methyl-D-aspartate receptor reveals drug interactions with the zinc and magnesium binding sites. J. Pharmacol. Exp. Ther. 247 (1988), 1025–1031.
180. Robson, M.J., Elliott, M., Seminerio, M.J., Matsumoto, R.R., Evaluation of sigma (sigma) receptors in the antidepressant-like effects of ketamine in vitro and in vivo. Eur. Neuropsychopharmacol. 22 (2012), 308–317.
181. Romo-Nava, F., Alvarez-Icaza Gonzalez, D., Fresan-Orellana, A., Saracco Alvarez, R., Becerra-Palars, C., Moreno, J., Ontiveros Uribe, M.P., Berlanga, C., Heinze, G., Buijs, R.M., Melatonin attenuates antipsychotic metabolic effects: an eight-week randomized, double-blind, parallel-group, placebo-controlled clinical trial. Bipolar Disord. 16 (2014), 410–421.
182. Salvatore, P., Ghidini, S., Zita, G., DePanfilis, C., Lambertino, S., Maggini, C., Baldessarini, R.J., Circadian activity rhythm abnormalities in ill and recovered bipolar I disorder patients. Bipolar Disord. 10 (2008), 256–265.
183. Sanacora, G., Johnson, M., Khan, A., Atkinson, S., Riesenberg, R., Schronen, J., Adjunctive lanicemine (AZD6765) in patients with major depressive disorder and a history of inadequate response to antidepressants: primary results from a randomized, placebocontrolled study (PURSUIT). Presented at the 53rd Meeting of the ACNP, Hollywood, FL, 2014.
184. Sanacora, G., Smith, M.A., Pathak, S., Su, H.L., Boeijinga, P.H., McCarthy, D.J., Quirk, M.C., Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol. Psychiatry 19 (2014), 978–985.
185. Sanacora, G., Treccani, G., Popoli, M., Towards a glutamate hypothesis of depression. An emerging fronteir of neuropsychopharmacology for mood disorders. Neuropharmacology 62 (2012), 63–77.
186. Saricicek, A., Maloney, K., Muralidharan, A., Ruf, B., Blumberg, H.P., Sanacora, G., Lorberg, B., Pittman, B., Bhagwagar, Z., Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 72 (2011), 744–750.
187. Scarr, E., Pavey, G., Sundram, S., MacKinnon, A., Dean, B., Decreased hippocampal NMDA, but not kainate or AMPA receptors in bipolar disorder. Bipolar Disord. 5 (2003), 257–264.
188. Schlaepfer, T.E., Bewernick, B.H., Kayser, S., Madler, B., Coenen, V.A., Rapid effects of deep brain stimulation for treatment-resistant major depression. Biol. Psychiatry 73 (2013), 1204–1212.
189. Schousboe, A., Bak, L.K., Waagepetersen, H.S., Astrocytic control of biosynthesis and turnover of the neurotransmitters glutamate and GABA. Front. Endocrinol. (Lausanne), 4, 2013, 102.
190. Shah, A., Carreno, F.R., Frazer, A., Therapeutic modalities for treatment resistant depression: focus on vagal nerve stimulation and ketamine. Clin. Psychopharmacol. Neurosci. 12 (2014), 83–93.
191. Sills, M.A., Loo, P.S., Tricyclic antidepressants and dextromethorphan bind with higher affinity to the phencyclidine receptor in the absence of magnesium and L-glutamate. Mol. Pharmacol. 36 (1989), 160–165.
192. Singh, J.B., Fedgchin, M., Daly, E., Xi, L., Melman, C., De Bruecker, G., Tadic, A., Sienaert, P., Wiegand, F., Manji, H.K., Drevets, W.C., Van Neuten, L., Efficacy and safety of intravenous esketamine in patients with treatment-resistant depression: a double-blind, double-randomization, placebo-controlled phase 2a study. Presented at the ACNP 52nd Annual Meeting, Hollywood, FL, 2013.
193. Singh, N.S., Zarate, C.A.J., Moaddel, R., Bernier, M., Wainer, I.W., What is hydroxynorketamine and what can it bring to neurotherapeutics?. Expert. Rev. Neurother. 14 (2014), 1239–1242.
194. Skolnick, P., Antidepressants for the new millennium. Eur. J. Pharmacol. 375 (1999), 31–40.
195. Skolnick, P., Modulation of glutamate receptors: strategies for the development of novel antidepressants. Amino Acids 23 (2002), 153–159.
196. Skolnick, P., Layer, R.T., Popik, P., Nowak, G., Paul, I.A., Trullas, R., Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry 29 (1996), 23–26.
197. Smith, E.G., Deligiannidis, K.M., Ulbricht, C.M., Landolin, C.S., Patel, J.K., Rothschild, A.J., Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 74 (2013), 966–973.
198. Srinivasan, V., Smits, M., Spence, W., Lowe, A.D., Kayumov, L., Pandi-Perumal, S.R., Parry, B., Cardinali, D.P., Melatonin in mood disorders. World J Biol. Psychiatry 7 (2006), 138–151.
199. Thomson, P.A., Wray, N.R., Thomson, A.M., Dunbar, D.R., Grassie, M.A., Condie, A., Walker, M.T., Smith, D.J., Pulford, D.J., Muir, W., Blackwood, D.H., Porteous, D.J., Sex-specific association between bipolar affective disorder in women and GPR50, an X-linked orphan G protein-coupled receptor. Mol. Psychiatry 10 (2005), 470–478.
200. Tizabi, Y., Bhatti, B.H., Manaye, K.F., Das, J.R., Akinfiresoye, L., Antidepressant-like effects of low ketamine dose is associated with increased hippocampal AMPA/NMDA receptor density ratio in female Wistar–Kyoto rats. Neuroscience 213 (2012), 72–80.
201. Trivedi, M.H., Rush, A.J., Wisniewski, S.R., Nierenberg, A.A., Warden, D., Ritz, L., Norquist, G., Howland, R.H., Lebowitz, B., McGrath, P.J., Shores-Wilson, K., Biggs, M.M., Balasubramani, G.K., Fava, M., Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 163 (2006), 28–40.
202. Trullas, R., Skolnick, P., Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur. J. Pharmacol. 185 (1990), 1–10.
203. Van Oekelen, D., Luyten, W.H., Leysen, J.E., 5-HT2A and 5-HT2C receptors and their atypical regulation properties. Life Sci. 72 (2003), 2429–2449.
204. Vetulani, J., Complex action of antidepressant treatment on central adrenergic system: possible relevance to clinical effects. Pharmacopsychiatry 17 (1984), 16–21.
205. Vieta, E., Thase, M.E., Naber, D., D'Souza, B., Rancans, E., Lepola, U., Olausson, B., Szamosi, J., Wilson, E., Hosford, D., Dunbar, G., Tummala, R., Eriksson, H., Efficacy and tolerability of flexibly-dosed adjunct TC-5214 (dexmecamylamine) in patients with major depressive disorder and inadequate response to prior antidepressant. Eur. Neuropsychopharmacol. 24 (2014), 564–574.
206. Voleti, B., Navarria, A., Liu, R.J., Banasr, M., Li, N., Terwilliger, R., Sanacora, G., Eid, T., Aghajanian, G., Duman, R.S., Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses. Biol. Psychiatry 74 (2013), 742–749.
207. Whalley, L.J., Perini, T., Shering, A., Bennie, J., Melatonin response to bright light in recovered, drug-free, bipolar patients. Psychiatry Res. 38 (1991), 13–19.
208. Wirz-Justice, A., Van den Hoofdakker, R.H., Sleep deprivation in depression: what do we know, where do we go?. Biol. Psychiatry 46 (1999), 445–453.
209. Wong, C.-S., Cherng, C.-H., Luk, H.-N., Ho, S.-T., Tung, C.-S., Effects of NMDA receptor antagonists on inhibition of morphine tolerance in rats: binding at μ-opioid receptors. Eur. J. Pharmacol. 297 (1996), 27–33.
210. Wood, J., Birmaher, B., Axelson, D., Ehmann, M., Kalas, C., Monk, K., Turkin, S., Kupfer, D.J., Brent, D., Monk, T.H., Nimgainkar, V.L., Replicable differences in preferred circadian phase between bipolar disorder patients and control individuals. Psychiatry Res. 166 (2009), 201–209.
211. Wu, J.C., Bunney, W.E., The biological basis of an antidepressant response to sleep deprivation and relapse: review and hypothesis. Am. J. Psychiatry 147 (1990), 14–21.
212. Wyatt, J.K., Dijk, D.J., Ritz-de Cecco, A., Czeisler, C.A., Sleep-facilitating effect of exogenous melatonin in healthy young men and women is circadian-phase dependent. Sleep 29 (2006), 609–618.
213. Yamanaka, H., Yokoyama, C., Mizuma, H., Kurai, S., Finnema, S.J., Halldin, C., Doi, H., Onoe, H., A possible mechanism of the nucleus accumbens and ventral pallidum 5-HT1B receptors underlying the antidepressant action of ketamine: a PET study with macaques. Transl. Psychiatry, 4, 2014, e342.
214. Yanagihara, Y., Ohtani, M., Kariya, S., Uchino, K., Hiraishi, T., Ashizawa, N., Aoyama, T., Yamamura, Y., Yamada, Y., Iga, T., Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. Biopharm. Drug Dispos. 24 (2003), 37–43.
215. Yang, C., Zhou, Z.Q., Gao, Z.Q., Shi, J.Y., Yang, J.J., Acute increases in plasma Mammalian target of rapamycin, glycogen synthase kinase-3b, and eukaryotic elongation factor 2 phosphorylation after ketamine treatment in three depressed patients. Biol. Psychiatry 73 (2013), e35–e36.
216. Yilmaz, A., Schulz, D., Aksoy, A., Canbeyli, R., Prolonged effect of an anesthetic dose of ketamine on behavioral despair. Pharmacol. Biochem. Behav. 71 (2002), 341–344.
217. Yu, J.J., Zhang, Y., Wang, Y., Wen, Z.Y., Liu, X.H., Qin, J., Yang, J.L., Inhibition of calcineurin in the prefrontal cortex induced depressive-like behavior through mTOR signaling pathway. Psychopharmacology (Berl.) 225 (2013), 361–372.
218. Zarate, C. Jr., Machado-Vieira, R., Henter, I., Ibrahim, L., Diazgranados, N., Salvadore, G., Glutamatergic modulators: the future of treating mood disorders?. Harv. Rev. Psychiatry 18 (2010), 293–303.
219. Zarate, C.A. Jr., Singh, J.B., Quiroz, J.A., De Jesus, G., Denicoff, K.K., Luckenbaugh, D.A., Manji, H.K., Charney, D.S., A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am. J. Psychiatry 163 (2006), 153–155.
220. Zarate, C.A., Mathews, D., Ibrahim, L., Chaves, J.F., Marquardt, C., Ukoh, I., Jolkovsky, L., Brutsche, N., Smith, M.A., Luckenbaugh, D., A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression. Biol. Psychiatry 74 (2013), 257–264.
221. Zarate, C.A., Mathews, D.C., Furey, M.L., Human biomarkers of rapid antidepressant effects. Biol. Psychiatry 73 (2013), 1142–1155.
222. Zarate, C.A., Quiroz, J.A., Singh, J.B., Denicoff, K.D., De Jesus, G., Luckenbaugh, D.A., Charney, D.S., Manji, H.K., An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol. Psychiatry 57 (2005), 430–432.
223. Zhou, W., Wang, N., Yang, C., Li, X.M., Zhou, Z.Q., Yang, J.J., Ketamine-induced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex. Eur. Psychiatry 29 (2014), 419–423.
224. Zimmer, E.R., Parent, M.J., Leuzy, A., Aliaga, A., Aliaga, A., Moquin, L., Schirrmacher, E.S., Soucy, J.P., Skelin, I., Gratton, A., Gauthier, S., Rosa-Neto, P., Imaging in vivo glutamate fluctuations with [(11)C]ABP688: a GLT-1 challenge with ceftriaxone. J. Cereb. Blood Flow Metab. 35 (2015), 1169–1174.
225. Zobel, A.W., Nickel, T., Kunzel, H.E., Ackl, N., Sonntag, A., Ising, M., Holsboer, F., Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiatr. Res. 34 (2000), 171–181.
226. Zoncu, R., Efeyan, A., Sabatini, D.M., mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 12 (2011), 21–35.
227. Zunszain, P.A., Horowitz, M.A., Cattaneo, A., Lupi, M.M., Pariante, C.M., Ketamine: synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties. Mol. Psychiatry 18 (2013), 1236–1241.